Drug Delivery Disposition and Dynamics

Developing medicines for the future

PhD program

Our PhD programs attract the best and brightest.

PhD students working in lab

Research areas

Find out about the types of research in the D4 theme and what we focus on.

Research groups

Our research groups are led by world-leading researchers.

Capabilities and research platforms

Our research is underpinned by significant technology infrastructure.

About us

Find out more about the D4 theme, who we are and what we do.

Laptop use

Contact us

For any enquiries please contact Nicki Penny at +61 3 9903 9614 or nicki.penny@monash.edu.

Latest news from D4

plume of oxytocin powder

Monash University completes recruitment for inhaled oxytocin clinical trial

A Monash-led Phase 1 clinical trial to assess the safety and performance of a novel oxytocin inhaler is now a step closer to completion with the conclusion of subject recruitment conducted by Nucleus Network located at the Alfred Hospital.

Professor Ben Boyd

Monash University Professor elevated to Fellow status by American Association of Pharmaceutical Sciences

Professor Ben Boyd is one of eight AAPS members selected for “elevation to Fellow status in recognition of their professional excellence and sustained superior impact in fields relevant to AAPS’ mission."

Nicolas Voelcker and Roey Elnathan

Nanoneedle breakthrough gives hope for cheaper cancer treatment

The breakthrough can improve outcomes in one of the world’s newest forms of cancer immunotherapies, CAR-T cell therapy.

Associate Professor Cornelia Landersdorfer and Hon. Minister Ben Carroll in the lab

Monash University and Moderna form partnership to advance homegrown mRNA medicines

The Monash-Moderna Quantitative Pharmacology Accelerator (MMQPA) is a five-year program which aims to drive advancements in mRNA medicines, including therapeutics and vaccines.

MRFF backs Australia’s first Drug Target Identification Platform

Australia will establish its first Drug Target Identification Platform to provide target identification services to the Australian drug discovery community.

Australian invention for potential treatment of anxiety disorders initiates Phase 2a Clinical Trial

The Glyph technology was initially developed by Professor Chris Porter and his team at MIPS and exclusively licensed to PureTech Health in 2017.

The Inhaled Oxytocin Project team

Clinical trial of inhaled oxytocin to reduce maternal mortality underway in Melbourne

A Phase 1 clinical trial led by Monash University to assess the safety and performance of a novel oxytocin inhaler in healthy, non-pregnant female volunteers has commenced in Melbourne.

South African delegation visits MIPS, scientists showcase mRNA innovations

MIPS has welcomed representatives from South Africa’s Afrigen Biologics and the South African Medical Research Council, along with mRNA Victoria, to meet with MIPS mRNA researchers who are working to identify and select promising therapeutic

Monash establishes new initiative to tackle inadequate access to safe and effective medicines in low-and middle-income countries

The initiative, co-founded by Pete Lambert and Professor Michelle McIntosh from MIPS, has been made possible due to a generous grant from The Ripple Foundation.

Other research themes